{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-003055","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.748462+00:00","generated_at":"2026-06-06T09:10:10.777490+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Genprex CFO to cover CEO during treatment; first patient dosed in Phase 2a expansion of Reqorsa","bullets":["Catherine Vaczy, EVP and General Counsel, resigned effective Feb 4; company and Vaczy in discussions.","CEO Rodney Varner undergoing treatment for cutaneous lymphoma; Board designates CFO Ryan Confer to act when CEO unavailable.","First patient dosed Jan 2024 in Phase 2a expansion of Acclaim-1 study (Reqorsa + Tagrisso for NSCLC).","Expects to complete Phase 2a enrollment (19 per cohort) by end of 2024; interim analysis in 2025.","Phase 1 data showed no dose-limiting toxicities and extended progression-free survival in some patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-003055","json":"https://secwatch.observer/filing/0001437749-24-003055.json","markdown":"https://secwatch.observer/filing/0001437749-24-003055.md","text":"https://secwatch.observer/filing/0001437749-24-003055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/gnpx20240204_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:10:10.777490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1de56e91fe","claim":"Ryan Confer changed role as Chief Financial Officer at Genprex, Inc..","evidence_excerpt":"the Board has determined that Mr. Confer can and shall act alone in covering when Mr. Varner is unavailable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"designated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"de600403d1","claim":"Catherine Vaczy resigned as Executive Vice President, General Counsel and Chief Strategy Officer at Genprex, Inc..","evidence_excerpt":"Catherine Vaczy, the Executive Vice President, General Counsel and Chief Strategy Officer of Genprex, Inc. (“Genprex” or the “Company”) notified the Company of her intention to resign. On February 4, 2024, Ms. Vaczy’s employment with the Company was terminated.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, General Counsel and Chief Strategy Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}